Loading provider…
Loading provider…
Cardiovascular Disease Physician in Stanford, CA
NPI: 1033260195Primary Practice Location
STANFORD HEALTH CARE
300 Pasteur Dr, Stanford, CA
Primary Employer
Stanford Hospital
stanfordhealthcare.org
HQ Phone
Get MB, FRCP Michael's Phone Numberphone_androidMobile
Get MB, FRCP Michael's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1986 - 2025
Charing Cross and Westminister Medical School
Medical School
Until 1975
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 81 | 90 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 43 | 53 |
| 3 | 93295Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 31 | 38 |
| 4 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 28 | 90 |
| 5 | 93284Evaluation, testing and programming adjustment of defibrillator with analysis, review and report, multiple lead defibrillator system | 26 | 28 |
Authors: Hartmann, Franz, Packer, Milton, Coats, Andrew J S, Fowler, Michael B, Krum, Henry, Mohacsi, Paul, Rouleau, Jean L, Tendera, Michal, Castaigne, Alain, Trawinski, Jürgen, Amann-Zalan, Ildiko, Hoersch, Silke, Katus, Hugo A
Journal: Eur J Heart Fail
The influence of beta-adrenergic blocking drugs on morbidity and mortality in heart failure.
Authors: @ValidYN, LastName, ForeName, Initials, AffiliationInfo
Journal: J Cardiovasc Risk
Authors: Timmis, A D, Fowler, M B, Chamberlain, D A
Journal: Br Med J (Clin Res Ed)
Lead Sponsor: Stanford University
Collaborators: Merck Sharp & Dohme LLC
Intervention / Treatment: DRUG: Sitagliptin
Lead Sponsor: Stanford University
Collaborators: Scios, Inc.
Intervention / Treatment: DRUG: Natrecor, a recombinant form of B-type Natriuretic Peptide, made by Scios, Inc. vs. placebo